tbuckley/cabot-search huggingface dataset:
Abstract P1-09-06: Biological Effects of Green Tea Capsule Supplementation in Pre-surgery Breast Cancer Patients
Authors: S Yu, D Spicer, D Hawes, A Wu
Journal: Cancer Research (2012)

Abstract Green tea is rich in antioxidant polyphenols consisting primarily of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (EGCG). There are suggestive evidence from observational epidemiologic studies that regular green tea consumers may have lower risk of breast cancer development and mortality. Inhibition of cell proliferation and angiogenesis and enhancement of apoptosis are some of the mechanisms that have been proposed to explain the anti-cancer actions of the bioactive extracts of green tea. We conducted a randomized pre-surgical pilot study of green tea capsules in women diagnosed with breast cancer at the Los Angeles County-University Southern California Medical Center. Women in both the green tea and control arms were non-green tea drinkers at baseline (i.e. less than 1 cup of green tea per week at the time of breast cancer diagnosis). Women (n = 17) who participated in the green tea arm took 3 green tea capsules daily (Pro Health Green Tea Mega EGCG, 3 capsules contained ∼ 870 mg EGCG; equivalent to ∼ 8 cups of green tea) between their breast cancer diagnosis until their scheduled surgery date. The average duration of green tea intake was 35 days. Women in the control arm did not drink green tea between diagnosis and surgery date. Participants in the green tea and control groups donated blood and urine specimens at enrollment and before surgery which were tested for urinary tea catechin levels as a measure of compliance. Baseline urinary tea catechin concentrations were low in both green tea and control arms. Tea catechin concentrations remained low for women in the control arm but increased significantly (2–10 folds for different catechins) for women in the green tea arm. The differences in pre-surgery urinary green tea levels were significantly different between these groups of participants We conducted standard immunohistochemical analysis of the formalin-fixed paraffin-embedded respective markers of cell proliferation (Ki67), apoptosis (BAX), and angiogenesis (CD34). Separate analysis was performed on benign and malignant breast cancer tissue. The changes in these three biomarkers pre- and post-treatment in the two groups will be presented. Supported by the WHH Foundation. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-09-06.
Abstract 3139: Frequent downregulation of NGB/GTPBP in lung cancer
Authors: Donghwa Kim, Sungman Park, Sang Haak Lee, Jong Y. Park, Jin Q. Cheng
Journal: Cancer Research (2012)

Abstract GTP-binding protein NGB (GTPBP4) is located at chromosome 10p14-p15, a region common loss in various types of human malignancy. Here, we demonstrated that NGB expression was frequently down-regulated in human lung cancer cell lines and primary tumors. Furthermore, we found hypermethylation in NGB promoter region. Treatment with trichostatin A (TSA) and 5-Aza-2′-deoxycytidine (5-Aza) restored NGB expression. In addition, the reintroduction of NGB into the cells, in which it is downregulated, represses cell growth, colony formation, angiogenesis and tumor growth in nude mouse. These findings indicate that NGB is a putative tumor suppressor gene in lung cancer and could play a pivotal role in lung carcinogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3139. doi:1538-7445.AM2012-3139
Abstract 4144: Circulating microRNAs as specific biomarkers for breast cancer
Authors: In Hae Park, Keun Seok Lee, Joo Hyun Kang, Jungsil Ro
Journal: Cancer Research (2012)

Abstract Background It has been reported that the cancer associated specific microRNAs were detected in blood. The objective of this study was to discover a panel of circulating microRNAs as potential ER+/HER2- breast cancer biomarkers. Methods We compared the levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients with age-matched 5 control subjects by using microarray-based expression profiling, which was subsequently validated by real-time quantitative polymerase chain reaction (RT-qPCR). We found that 4 microRNAs (miR-1280, miR-1260, miR-1274b, miR-720) were up-regulated in blood from breast cancer patients (P&amp;lt;0.05, constrained by at least two-fold expression change). We identified the levels of above 4 and additional three microRNAs (miR-21, miR-195, and let-7a) in 40 control subjects, 44 early breast cancer patients (EBC), and 22 metastatic breast cancer patients (MBC). The levels of miR-1280 and miR-1260 in blood were significantly different by the disease status (control&amp;lt;EBC&amp;lt;MBC) (Table 1). The level of let-7a was higher in cancer patients (P&amp;lt;0.001), while there was no difference in the level of let-7a between patients with EBC and those with MBC (P=0.422). Using receiver operational curve (ROC) analysis, blood levels of miR-1280 could detect patients with breast cancer with 85% specificity and 81% sensitivity; while blood let-7a levels could discriminate cancer patients with 90% specificity and 95.2% sensitivity. Conclusions These findings suggest that blood microRNAs are differentially expressed in breast cancer patients, which can be used as potential biomarkers for breast cancer. Table 1. Mean expression levels (SD) of target microRNAs in blood from breast cancer patients compared with blood from healthy controls. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4144. doi:1538-7445.AM2012-4144
PRIOR FAILURE DOES NOT HAVE SIGNIFICANT IMPACT ON PROCEDURAL OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM A CONTEMPORARY MULTICENTER REGISTRY
Authors: Judit Karacsonyi, Aris Karatasakis, Dimitri Karmpaliotis, Khaldoon Alaswad, Robert Yeh, Farouc Jaffer, R. Michael Wyman, William Lombardi, Aaron Grantham, David Kandzari, Nicholas Lembo, Jeffrey Moses, Ajay Kirtane, Manish Parikh, Santiago Garcia, Anthony Doing, Mitul Patel, John Bahadorani, Jose Roberto Martinez Parachini, Erica Resendes, Bavana Rangan, Imre Ungi, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2016)
SP0176 Healthy Aging! Preventing Falls in People with RMDS
Authors: C. Ioulianos
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> As we grow older, many changes happen in our physiological condition, namely in the musculoskeletal, central nervous and cardiovascular systems, resulting in a decrease in muscle mass, strength, power, endurance, as well as a decrease in instability, proprioception, gait velocity and stability etc. At the same time there is an increase in blood pressure, fat mass e.a, all of which mean a lower quality of life for the elderly. People with RMDs experience these symptoms in a faster and more intense way. One of the most dangerous aspects of aging is instability and falling, or even fear of falling, because of various reasons, such as impaired muscle strength, postural inability e.a. The importance of exercise in both preventing falls and increasing self-confidence has long been scientifically established. A suggested sensorimotor training progression, based on the principles of proprioception is presented and analyzed in its three stages/levels: first, the static level, then the dynamic and, lastly, the functional. Conclusively, despite the discouraging changes in the physiological condition of the elderly and especially with people with RMDs, if a progressive and continuous exercise programme is followed through, the risk of falling can be decreased and the quality of life can be increased. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6236
Abstract P2-02-01: Characterization of the Breast Lesions by Biexponential Signal Attenuation Analysis of Diffusion-Weighted Magnetic Resonance Images
Authors: T Tamura, S Murakami, K Arihiro, S Usui, K Naito, M. Akiyama
Journal: Cancer Research (2010)

Abstract Purpose: Signal attenuation of diffusion-weighted magnetic resonance images (DWI) in vivo with high b-values is sometimes non-linear when plotted with a semilogarithmic function, but it fits well with the biexponential equation, Sb/S0=f1exp(bD1) + (1-f1)(bD2). Others have indicated that the fast and slow component fractions (f1, 1-f1) of the apparent diffusion coefficients (D1, D2) can be derived by biexponential fitting, and that these fractions correspond to actual diffusion components in the extra-and intracellular space. Here, we investigated the clinical value of DWI for breast screening by performing multi b-factor DWI on healthy volunteers and patients. We then analyzed signals by fitting them with the biexponential equation and compared the fitting parameters of breast lesions. Patients and methods: This study was approved by our center's institutional review board and all patients and volunteers gave their informed consent. We analyzed data from eight healthy females (controls) and 80 female patients with a total of 100 breast tumors (42 benign and 58 malignant). We performed DWI using 12 and 6 b-values for the controls and patients up to a maximum b-value of 3500 sec/mm2. Results: We identified the DWI signal attenuation features of the normal mammary gland, and of benign and malignant tumors [Figure1]. The DWI signal attenuation was similar between some proliferative benign tumors and malignancies. A comparison of the parameters derived from biexponential fitting revealed a significant difference in f1 between noninvasive and invasive ductal carcinoma [Figure 2]. Conclusion: The biexponential fitting parameters might reflect the features of tumor cellularity. Thus, to distinguish malignant from benign breast tumors only by DWI is difficult due to the pathological diagnosis that rather emphasizes cell configuration or shape rather than cellularity. Nevertheless, our findings will help to understand why malignant tumors present as high signal intensity in DWI. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-02-01.
P663 IMPACT OF HEPATIC FLARE ON THE LONG-TERM DECLINE IN HEPATITIS B SURFACE ANTIGEN TOWARD ITS SEROCLEARANCE IN CHRONIC HBV CARRIERS: A SINGLE CENTER RETROSPECTIVE ANALYSIS
Authors: S. Nagaoka, J. Shiota, Y. Kugiyama, Y. Miyazoe, R. Sasaki, S. Bekki, S. Hashimoto, A. Saeki, S. Abiru, K. Yamasaki, A. Komori, H. Yatsuhashi
Journal: Journal of Hepatology (2014)
Cerebellar theory out of control
Authors: Michael G. Paulin
Journal: Behavioral and Brain Sciences (1996)

The views of Houk et al., Smith, and Thach on the role of cerebellum in movement control differ substantially, but all three are flawed by the false reasoning that because information passes from the cerebellum to movements the cerebellum must be a movement controller, or a part of one. The divergent and less than compelling ideas expressed by these leading cerebellar theorists epitomize the fruitlessness of this paradigm, and signal the need for a change. [HOUK et al.; SMITH; THACH]
Abstract 5532: Folate receptor expression in human malignancies to select patients who would benefit from folate conjugated therapy
Authors: Kelly L. Covello, Amy Wiebesiek, Leila Alland, Yijin She, Qiuyan Wu, Francis Lee
Journal: Cancer Research (2010)

Abstract The folate receptor (FR) is expressed on a number of human tumors, including ovarian, renal, lung, and breast. Folic acid is the ligand for the FR and many innovative strategies for targeting therapeutics to tumors make use of this ligand/receptor pair. Novel therapeutic approaches include folate conjugation to cytotoxics or radiopharmaceuticals, folate-coated liposomes containing antisense oligonucleotides, folate conjugates of pro-drugs, and folate-linked nanoparticle carriers for therapeutic drugs and genes. Potential patient enrichment strategies are necessary to allow for better targeting of these agents to those patients who have FR expressing tumors. Preclinical experiments to evaluate the molecular correlation of FR levels by three different methods, qRT-PCR, IHC, and the radiolabeled ligand binding assay, were conducted. A total of seventeen samples (four xenografts and thirteen primary patient ovarian and endometrial tumor biopsies) were evaluated for FR expression in these three independent assays and the FR levels correlated in this sample size. Compared to a preclinical model that was sensitive to epothilone-folate conjugate therapy, most patient samples expressed higher FR levels. These data provide a reliable and useful method to identify patient tumors that express the FR above a baseline determined to be sufficient for response to folate-conjugated therapy in preclinical models. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5532.
MULTICENTER STUDY OF THE ABILITY OF NUCLEAR TECHNOLOGISTS AND AUTOMATED QUANTIFICATION TO DETERMINE THE NEED FOR REST IMAGING IN A STRESS-FIRST MYOCARDIAL PERFUSION IMAGING (MPI) PROTOCOL
Authors: Waseem Chaudhry, Nasir Hussain, Alan Ahlberg, Piotr Slomka, Milena Henzlova, William Duvall
Journal: Journal of the American College of Cardiology (2015)
Abstract P6-05-03: Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer
Authors: BD Lehmann, JA Bauer, JM Schafer, L Tang, CS Pendleton, ME Sanders, JA Pietenpol
Journal: Cancer Research (2012)

Abstract Triple negative breast cancers (TNBC) are generally more aggressive than other types of breast cancer, with higher rates of relapse in the early stage and decreased overall survival in the metastatic setting. TNBC has been particularly difficult to treat given that the biology of the disease is not well understood, and until recently, molecular targets for therapeutic intervention have remained elusive. Lacking HER2 amplification as well as estrogen and progesterone receptors, TNBC appears to be a heterogeneous collection of biologically diverse cancers, which likely contributes to variable clinical outcomes for patients suffering from this disease. Using gene expression analyses, we recently identified six distinct molecular TNBC subtypes with unique biologies that include two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. We demonstrated that the growth of LAR cell line models was dependent on AR signaling, as siRNA-mediated AR knockdown or pharmacological inhibition by bicalutamide greatly diminished viability. In addition we previously demonstrated that LAR cell lines are highly sensitive to the PI3K/mTOR inhibitor NVP-BEZ235. Interestingly, we observed that all AR-positive TNBC cell lines examined contain PIK3CA mutations (H1047R) suggesting selection for deregulation of the PI3K pathways during evolution of AR expressing breast cancers. Further investigation of a panel of AR-positive TNBC tumors showed that PIK3CA kinase mutations are a frequent event in this TNBC subtype (69.2% vs. 26.9%) and not just an artifact of the LAR cell line models. We show that PI3K pathway activation plays a role in resistance to AR antagonists, as there are elevated levels of activated AKT in residual tumors after bicalutamide treatment of xenograft tumors. Furthermore, we demonstrate that genetic/pharmacological targeting of AR synergizes with PI3K/mTOR inhibition in both two- and three-dimensional cell culture models. Moreover, the combination of bicalutamide with PI3K/mTOR inhibitors GDC0980 or NVP-BEZ235 decreased tumor volume in mouse xenograft studies. Our preclinical data provide the rationale for pre-selecting AR-positive TNBC patients for future clinical trials evaluating the combination of AR antagonists with PI3K/mTOR inhibitors. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-05-03.
EXTRACELLULAR MATRIX TURNOVER IS NOT RELATED TO THE DURATION OF THE DISEASE IN DILATED CARDIOMYOPATHY
Authors: Pawel Rubis, Sylwia Wisniowska-Smialek, Ewa Wypasek, Lucyna Rudnicka-Sosin, Barbara Biernacka-Fijalkowska, Artur Kozanecki, Piotr Podolec
Journal: Journal of the American College of Cardiology (2016)
The Association of Floppy Mitral Valve with Disjunction of the Mitral Annulus Fibrosus
Authors: Grover M. Hutchins, G. William Moore, Dagna K. Skoog
Journal: New England Journal of Medicine (1986)

Floppy mitral valve is usually attributed to connective-tissue degeneration. However, we have observed several instances in which both a floppy mitral valve and an abnormal mitral annulus fibrosus were present at autopsy. To study this association, we examined 900 hearts (after postmortem arteriography and fixation in distention) from autopsies of adults at The Johns Hopkins Hospital. Twenty-five (3 percent) of the hearts had a morphologically typical floppy mitral valve; in 23 of them (92 percent), the mitral annulus fibrosus showed disjunction--i.e., a separation between the atrial wall-mitral valve junction and the left ventricular attachment. In 42 other hearts (5 percent), which were from significantly younger patients (mean age [+/- SE], 60 +/- 2 years vs. 68 +/- 3; P less than 0.05), there was mitral annulus disjunction but no floppy mitral valve. Two hearts had a floppy mitral valve but no disjunction of the annulus; both of them had old infarcts of the papillary muscle. Our results show that floppy mitral valve is significantly associated with disjunction of the mitral annulus fibrosus (P less than 0.001). We suggest that floppy mitral valve develops from hypermobility of the valve apparatus, and that it is usually secondary to disjunction of the mitral annulus fibrosus, an anatomic variation in the morphology of the annulus.
Human Infection with a Novel Avian Influenza A(H5N6) Virus
Authors: Zi-Feng Yang, Chris K P Mok, Joseph S M Peiris, Nan-Shan Zhong
Journal: New England Journal of Medicine (2015)

To the Editor: Multiple reassortant strains of novel, highly pathogenic avian influenza A(H5) viruses in clade 2.3.4.4 have recently emerged and spread in Asia, Europe, and North America, giving rise to multiple subtypes (H5N2, H5N5, H5N6, and H5N8).1–3 We report on a 59-year-old man in Guangzhou, China, with influenza A(H5N6) infection and associated illness. He had a 30-year history of smoking and had stopped smoking in January 2014. He had undergone surgery and chemotherapy for colon cancer, the last chemotherapy dose having been administered in April 2014. During the weeks before illness onset, he regularly purchased and handled live . . .
Abstract 690: Discovery and preliminary validation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study
Authors: Christopher I. Li, Justin Mirus, Yuzheng Zhang, Martin W. McIntosh, Paul D. Lampe
Journal: Cancer Research (2012)

Abstract Background: One approach to develop new tools for detecting cancer early is through the identification and validation of blood-based cancer specific biomarkers. In applying this approach to breast cancer one potential challenge is the disease's considerable heterogeneity. Triple-negative (TN) breast cancer is a particularly lethal breast cancer subtype that is known to have a unique biology. Consequently, there is a clinical need to discover early detection biomarkers for TN disease, and such biomarkers may be more readily identifiable given the more aggressive nature and growth patterns of these tumors. Objective: To discover and initially validate novel TN breast cancer specific early detection biomarkers using preclinical plasma samples. Methods: We conducted a nested case-control study of TN breast cancer within the Women's Health Initiative (WHI) Observational Study (OS) consisting of 28 TN cases whose blood was drawn 17 months prior to their breast cancer diagnosis and an equal number of matched controls. The 28 matched sets were equally divided into a training set, used for discovery, and an independent test set, used for validation, and interrogated using a customized antibody microarray. Results: In the training set, of the 915 antibodies assessed, 55 (6.0%) were statistically significantly different between cases and controls at p&amp;lt;0.05 and in the test set 128 (14.0%) were statistically different. Of the 55 candidates identified in the training set, 15 were validated in the test set at p&amp;lt;0.05. Of these 15 candidates, 13 had higher levels in cases compared to controls. The candidates with the strongest signals included myosin-5A (log2 ratio=1.26), arfaptin-2 (log2 ratio=1.02), integrin-beta1 (log2 ratio=0.99), phosphoserine aminotransferase (log2 ratio=0.94), beta-catenin (log2 ratio=0.92), mast/stem cell growth factor receptor (log2 ratio=0.90), and IGFBP-2 (log2 ratio=−1.18). Conclusions: Several unique, novel candidate early detection biomarkers specific to TN breast cancer were discovered and initially validated in preclinical samples. These findings warrant validation in additional sets of TN cases and controls to further evaluate their potential clinical significance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 690. doi:1538-7445.AM2012-690
Ineffectiveness of Prophylactic Epsilon Aminocaproic Acid in Severe Hemophilia
Authors: Herbert S. Strauss, Sherwin V. Kevy, Louis K. Diamond
Journal: New England Journal of Medicine (1965)

SUBSTANTIAL advances have been made in recent years in the treatment of hemorrhage and management of surgical situations in hemophilia by replacement therapy employing plasma and various plasma fractions. Replacement therapy, however, is not suitable as a preventive measure because of its short-lived corrective effect and the risk of inhibitor formation. Attempts to modify the disease have often resulted in enthusiastic promotion of new methods of therapy that lacked objectivity. For example, recent reports have indicated a beneficial effect of peanuts or peanut extracts in preventing or ameliorating hemorrhage in hemophilia.1 2 3 4 This was initially attributed to a vasoconstrictive effect by . . .